Akero Therapeutics, Inc. (AKRO): Price and Financial Metrics

Akero Therapeutics, Inc. (AKRO): $8.84

0.56 (+6.76%)

POWR Rating

Component Grades













Add AKRO to Watchlist
Sign Up

Industry: Biotech



in industry

AKRO Stock Price Chart Interactive Chart >

Price chart for AKRO

AKRO Price/Volume Stats

Current price $8.84 52-week high $30.53
Prev. close $8.28 52-week low $7.88
Day low $8.01 Volume 216,000
Day high $8.87 Avg. volume 233,301
50-day MA $11.78 Dividend yield N/A
200-day MA $18.63 Market Cap 309.60M

Akero Therapeutics, Inc. (AKRO) Company Bio

Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

AKRO Latest News Stream

Event/Time News Detail
Loading, please wait...

AKRO Latest Social Stream

Loading social stream, please wait...

View Full AKRO Social Stream

Latest AKRO News From Around the Web

Below are the latest news stories about Akero Therapeutics Inc that investors may wish to consider to help them evaluate AKRO as an investment opportunity.

Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year

GlobeNewswire | February 25, 2022

Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Akero Therapeutics (AKRO)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics (KPTI – Research Report) and Akero Therapeutics (AKRO – Research Report) with bullish sentiments. Karyopharm Therapeutics (KPTI) H.C. Wainwright analyst Edward White maintained a Buy rating on Karyopharm Therapeutics today and set a price target of $26.00. The company's shares closed last Wednesday at $9.13. According to TipRanks.

Brian Anderson on TipRanks | February 9, 2022

Akero finishes enrollment in phase 2b trial of efruxifermin in liver disease

Akero Therapeutics (AKRO -0.2%) completed enrollment in a phase 2b study, dubbed HARMONY, evaluating efruxifermin (EFX) to treat non-alcoholic steatohepatitis (NASH). "Our confidence in EFX’s potential is based on Phase 2a data that showed substantial rates of fibrosis regression after only 16 weeks of treatment. We believe the larger Phase 2b HARMONY...

Seeking Alpha | February 8, 2022

Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that it has completed enrollment of the Phase 2b HARMONY study of efruxifermin (EFX), a novel FGF21 analog, for the treatment of non-alcoholic steatohepatitis (NASH).

GlobeNewswire | February 8, 2022

Is Akero Therapeutics, Inc. (AKRO) Outperforming Other Medical Stocks This Year?

Here is how Akero Therapeutics, Inc. (AKRO) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.

Yahoo | January 14, 2022

Read More 'AKRO' Stories Here

AKRO Price Returns

1-mo -15.73%
3-mo -50.14%
6-mo -58.42%
1-year -66.23%
3-year N/A
5-year N/A
YTD -58.20%
2021 -18.02%
2020 16.24%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6226 seconds.